|
|
1.
|
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. MedStar authors:
Year: 2013
Citation: - Oncologist. 18(3):257-64, 2013.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Amadori D, Baselga J, Benyunes MC, Clark E, Cortes J, Ewer MS, Knott A, Miles D, Ross G, Swain SM
|
|
|
2.
|
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. MedStar authors:
- Asch, Federico M
- Barac, Ana
- Cunningham, A
- Gallagher, Christopher
- Hofmeyer, Mark
- Srichai, M B
- Swain, Sandra M
Year: 2019
Citation: - Breast Cancer Research & Treatment. 175(3):595-603, 2019 Jun.
Institution:
- MedStar Health
- MedStar Health Research Institute
- MedStar Heart & Vascular Institute
- Washington Cancer Institute
Department: - Associate Dean for Research Development
Medline publication type:
All authors: - Asch FM, Barac A, Cunningham A, Dang C, Gallagher C, Geng X, Herbolsheimer P, Hofmeyer M, Isaacs C, Lynce F, Nunes R, Pohlmann PR, Shajahan-Haq A, Smith KL, Srichai MB, Swain SM, Tan MT, Timothee P, Warren R, Yu AF
|
|
|
3.
|
SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. MedStar authors:
- Asch, Federico M
- Barac, Ana
- Lynce, Filipa
- Swain, Sandra M
Year: 2017
Citation: - Oncologist. 22(5):518-525, 2017 May
Institution:
- MedStar Heart & Vascular Institute
- Washington Cancer Institute
Medline publication type:
All authors: - Asch FM, Barac A, Dang C, Isaacs C, Lynce F, Smith KL, Swain SM, Tan MT
|
